A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).
Non Small Cell Lung Cancer
DRUG: STA 9090
Progression Free Survival rate, 16 weeks
Objective Response Rate, Disease Control Rate, Progression Free Survival, Overall Survival, 18 months|Safety and tolerability as measured by adverse event rates and laboratory evaluations, 16 months
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).